92 related articles for article (PubMed ID: 32293976)
21. Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study.
Lee MK; Lee WJ; Do YR; Lee KS; Jung KH; Heo DS; Kim SY; Park SY; Jeong HS; Kang JH; Kim SY; Park SR; Yun YH
Palliat Support Care; 2015 Aug; 13(4):1103-11. PubMed ID: 25192193
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
23. Preferences for Life-Sustaining Treatments and Associations With Accurate Prognostic Awareness and Depressive Symptoms in Terminally Ill Cancer Patients' Last Year of Life.
Tang ST; Wen FH; Hsieh CH; Chou WC; Chang WC; Chen JS; Chiang MC
J Pain Symptom Manage; 2016 Jan; 51(1):41-51.e1. PubMed ID: 26386187
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies.
Sheng J; Zhang YX; He XB; Fang WF; Yang YP; Lin GN; Wu X; Li N; Zhang J; Zhai LZ; Zhao YY; Huang Y; Zhou NN; Zhao HY; Zhang L
Oncologist; 2017 Jan; 22(1):53-60. PubMed ID: 27789776
[TBL] [Abstract][Full Text] [Related]
25. Multicenter cohort study on the survival time of cancer patients dying at home or in a hospital: Does place matter?
Hamano J; Yamaguchi T; Maeda I; Suga A; Hisanaga T; Ishihara T; Iwashita T; Kaneishi K; Kawagoe S; Kuriyama T; Maeda T; Mori I; Nakajima N; Nishi T; Sakurai H; Shimoyama S; Shinjo T; Shirayama H; Yamada T; Morita T
Cancer; 2016 May; 122(9):1453-60. PubMed ID: 27018875
[TBL] [Abstract][Full Text] [Related]
26. Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer.
Lopez-Acevedo M; Havrilesky LJ; Broadwater G; Kamal AH; Abernethy AP; Berchuck A; Alvarez Secord A; Tulsky JA; Valea F; Lee PS
Gynecol Oncol; 2013 Jul; 130(1):156-61. PubMed ID: 23587882
[TBL] [Abstract][Full Text] [Related]
27. Preferences for Aggressive End-of-life Care and Their Determinants Among Taiwanese Terminally Ill Cancer Patients.
Liu LN; Chen CH; Liu TW; Lin YC; Lee SC; Tang ST
Cancer Nurs; 2015; 38(3):E9-E18. PubMed ID: 24915466
[TBL] [Abstract][Full Text] [Related]
28. Associations between accurate prognostic understanding and end-of-life care preferences and its correlates among Taiwanese terminally ill cancer patients surveyed in 2011-2012.
Tang ST; Liu TW; Chow JM; Chiu CF; Hsieh RK; Chen CH; Liu LN; Feng WL
Psychooncology; 2014 Jul; 23(7):780-7. PubMed ID: 24470441
[TBL] [Abstract][Full Text] [Related]
29. Engaging Terminally Ill Patients in End of Life Talk: How Experienced Palliative Medicine Doctors Navigate the Dilemma of Promoting Discussions about Dying.
Pino M; Parry R; Land V; Faull C; Feathers L; Seymour J
PLoS One; 2016; 11(5):e0156174. PubMed ID: 27243630
[TBL] [Abstract][Full Text] [Related]
30. Factors Predisposing Terminally Ill Cancer Patients' Preferences for Distinct Patterns/States of Life-Sustaining Treatments Over Their Last Six Months.
Wen FH; Chen JS; Chou WC; Chang WC; Hsieh CH; Tang ST
J Pain Symptom Manage; 2019 Feb; 57(2):190-198.e2. PubMed ID: 30447386
[TBL] [Abstract][Full Text] [Related]
31. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
Lydiksen L; Jensen-Fangel S; Blaakaer J
Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
[TBL] [Abstract][Full Text] [Related]
32. Aggressive anticancer treatment in the last 2 weeks of life.
Golob N; Oblak T; Čavka L; Kušar M; Šeruga B
ESMO Open; 2024 Mar; 9(3):102937. PubMed ID: 38471241
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
34. Does awareness of terminal status influence survival and quality of life in terminally ill cancer patients?
Kim SY; Kim JM; Kim SW; Shin IS; Bae KY; Shim HJ; Hwang JE; Bae WK; Cho SH; Chung IJ; Yoon JS
Psychooncology; 2013 Oct; 22(10):2206-13. PubMed ID: 23505129
[TBL] [Abstract][Full Text] [Related]
35. Does complete-staging lymphadenectomy improve survival outcomes in stage I endometrioid epithelial ovarian carcinoma? A multi-institutional retrospective study with propensity score-weighted analysis.
Yoshihara M; Tamauchi S; Iyoshi S; Kitami K; Uno K; Tano S; Matsui S; Kajiyama H
Jpn J Clin Oncol; 2021 Mar; 51(3):387-392. PubMed ID: 33253382
[TBL] [Abstract][Full Text] [Related]
36. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of tonsillectomy for IgA nephropathy patients: A retrospective cohort study, two-centre analysis with the inverse probability therapy weighting method.
Matsumoto K; Ikeda Y; Yamaguchi S; Sanematsu M; Fukuda M; Takashima T; Kishi T; Miyazono M; Uchiumi S; Yoshizaki M; Nonaka Y; Matsumoto R; Kanaya A; Fukunari K; Ikeda Y
Nephrology (Carlton); 2018 Sep; 23(9):846-854. PubMed ID: 28703898
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.
Seisen T; Krasnow RE; Bellmunt J; Rouprêt M; Leow JJ; Lipsitz SR; Vetterlein MW; Preston MA; Hanna N; Kibel AS; Sun M; Choueiri TK; Trinh QD; Chang SL
J Clin Oncol; 2017 Mar; 35(8):852-860. PubMed ID: 28045620
[TBL] [Abstract][Full Text] [Related]
39. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
40. Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area.
Yu Y; Liang H; Lv X; Ke L; Qiu W; Huang X; Liu G; Li W; Guo X; Xiang Y; Xia W
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2231-2243. PubMed ID: 30109501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
